DK1121111T3 - Forbindelser til behandling af vægttab - Google Patents

Forbindelser til behandling af vægttab

Info

Publication number: DK1121111T3
Authority: DK; Denmark
Prior art keywords: patient; receptor antagonist; weight loss; inhibitor; administering
Prior art date: 1998-10-15

Application number

DK99947762.3T

Other languages

English (en)

Inventor

Andrew Coats

Stefan Anker

Original Assignee

Imp Innovations Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-15

Filing date

1999-10-15

Publication date

2010-05-31

1998-10-15 Priority claimed from GBGB9822459.5A external-priority patent/GB9822459D0/en

1998-10-15 Priority claimed from GBGB9822458.7A external-priority patent/GB9822458D0/en

1999-07-23 Priority claimed from GBGB9917181.1A external-priority patent/GB9917181D0/en

1999-10-15 Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd

2010-05-31 Application granted granted Critical

2010-05-31 Publication of DK1121111T3 publication Critical patent/DK1121111T3/da

Links

208000016261 weight loss Diseases 0.000 title abstract 3
230000004580 weight loss Effects 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 title abstract 2
230000000694 effects Effects 0.000 abstract 4
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
229940044551 receptor antagonist Drugs 0.000 abstract 2
239000002464 receptor antagonist Substances 0.000 abstract 2
229930000680 A04AD01 - Scopolamine Natural products 0.000 abstract 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 abstract 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
229940123329 Cathepsin B inhibitor Drugs 0.000 abstract 1
229940119334 Chymase inhibitor Drugs 0.000 abstract 1
229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 abstract 1
229940096915 Imidazoline receptor antagonist Drugs 0.000 abstract 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 abstract 1
229960002478 aldosterone Drugs 0.000 abstract 1
229940083712 aldosterone antagonist Drugs 0.000 abstract 1
239000002170 aldosterone antagonist Substances 0.000 abstract 1
239000002876 beta blocker Substances 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000003601 chymase inhibitor Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
239000003457 ganglion blocking agent Substances 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
229940127240 opiate Drugs 0.000 abstract 1
230000011514 reflex Effects 0.000 abstract 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 abstract 1
229960002646 scopolamine Drugs 0.000 abstract 1
210000002820 sympathetic nervous system Anatomy 0.000 abstract 1
229940075420 xanthine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Hematology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)
Gastroenterology & Hepatology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Glass Compositions (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Signal Processing For Digital Recording And Reproducing (AREA)
External Artificial Organs (AREA)

DK99947762.3T 1998-10-15 1999-10-15 Forbindelser til behandling af vægttab DK1121111T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB9822459.5A GB9822459D0 (en)	1998-10-15	1998-10-15	Method of treatment
GBGB9822458.7A GB9822458D0 (en)	1998-10-15	1998-10-15	Methods of treatment
GBGB9917181.1A GB9917181D0 (en)	1999-07-23	1999-07-23	Methods of treatment
PCT/GB1999/003302 WO2000021509A2 (en)	1998-10-15	1999-10-15	Methods of treatment

Publications (1)

Publication Number	Publication Date
DK1121111T3 true DK1121111T3 (da)	2010-05-31

Family

ID=27269516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99947762.3T DK1121111T3 (da)	1998-10-15	1999-10-15	Forbindelser til behandling af vægttab

Country Status (9)

Country	Link
US (2)	US7417038B1 (da)
EP (1)	EP1121111B1 (da)
JP (1)	JP2002527378A (da)
AT (1)	ATE457169T1 (da)
CY (1)	CY1110282T1 (da)
DE (1)	DE69942009D1 (da)
DK (1)	DK1121111T3 (da)
PT (1)	PT1121111E (da)
WO (1)	WO2000021509A2 (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7417038B1 (en) *	1998-10-15	2008-08-26	Imperial Innovations Limited	Methods of treating cachexia
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
GB0219660D0 (en)	2002-08-23	2002-10-02	Astrazeneca Ab	Therapeutic use
US20040122067A1 (en) *	2002-12-20	2004-06-24	Lin Zhao	Treatment of chronic heart failure
ATE547404T1 (de)	2003-09-22	2012-03-15	Msd Kk	Piperidinderivate
JP4664924B2 (ja)	2003-12-02	2011-04-06	ウーツェーベーファルマゲーエムベーハー	中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
GB0403744D0 (en)	2004-02-20	2004-03-24	Astrazeneca Ab	Chemical process
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
EP1604655A1 (en)	2004-06-09	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1784390A2 (en)	2004-08-13	2007-05-16	Amgen Inc.	Substituted benzofused heterocycles
US7528175B2 (en) *	2004-10-08	2009-05-05	Inverseon, Inc.	Method of treating airway diseases with beta-adrenergic inverse agonists
CN101094689B (zh)	2004-11-01	2013-06-12	安米林药品有限责任公司	治疗肥胖以及肥胖相关疾病和病症的方法
WO2007022123A2 (en)	2005-08-11	2007-02-22	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
WO2006102476A2 (en) *	2005-03-21	2006-09-28	Vicus Therapeutics Spe 1, Llc	Compositions and methods for ameliorating cachexia
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610580B8 (pt)	2005-05-30	2021-05-25	Banyu Pharma Co Ltd	composto derivado de piperidina
JPWO2007018248A1 (ja)	2005-08-10	2009-02-19	萬有製薬株式会社	ピリドン化合物
EP2330125A3 (en)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
WO2007024004A1 (ja)	2005-08-24	2007-03-01	Banyu Pharmaceutical Co., Ltd.	フェニルピリドン誘導体
EP1940842B1 (en)	2005-09-29	2012-05-30	Merck Sharp & Dohme Corp.	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2009512715A (ja)	2005-10-21	2009-03-26	ノバルティスアクチエンゲゼルシャフト	レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
IE20050723A1 (en) *	2005-10-28	2007-05-30	Patrick T Prendergast	Anti-mineralocorticoid therapy of infection
WO2007144195A2 (en)	2006-06-15	2007-12-21	Schwarz Pharma Ag	Pharmaceutical composition with synergistic anticonvulsant effect
US8173629B2 (en)	2006-09-22	2012-05-08	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en)	2006-09-28	2009-10-01	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
GB0624282D0 (en)	2006-12-05	2007-01-10	Cavalla David	Treatment of cachexia
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2264026A4 (en)	2008-03-06	2012-03-28	Msd Kk	ALKYLAMINOPYRIDINDERIVATE
WO2009119726A1 (ja)	2008-03-28	2009-10-01	萬有製薬株式会社	メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
ES2522968T3 (es)	2008-06-04	2014-11-19	Synergy Pharmaceuticals Inc.	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2009149493A1 (en) *	2008-06-09	2009-12-17	Dimerix Bioscience Pty Ltd	Novel receptor hetero-dimers/-oligomers
JPWO2009154132A1 (ja)	2008-06-19	2011-12-01	Ｍｓｄ株式会社	スピロジアミン−ジアリールケトオキシム誘導体
AU2009270833B2 (en)	2008-07-16	2015-02-19	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
RU2392933C2 (ru) *	2008-07-18	2010-06-27	Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН)	Средство, обладающее гиполипидемическими свойствами
EP2319841A1 (en)	2008-07-30	2011-05-11	Msd K.K.	(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2732513C (en)	2008-08-01	2017-04-25	Arca Biopharma, Inc.	Methods and compositions involving (s)-bucindolol
EP2348857B1 (en)	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en)	2008-10-31	2012-12-11	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (en)	2008-12-16	2011-10-26	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
GB0907350D0 (en) *	2009-04-29	2009-06-10	Myotec Therapeutics Ltd	Methods
JP5602250B2 (ja)	2010-01-14	2014-10-08	ノバルティスアーゲー	副腎ホルモン修飾剤の使用
US20120296403A1 (en)	2010-02-10	2012-11-22	Novartis Ag	Methods and compounds for muscle growth
JP2013520502A (ja)	2010-02-25	2013-06-06	メルク・シャープ・エンド・ドーム・コーポレイション	有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en)	2011-02-25	2013-09-30	Merck Sharp & Dohme	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
KR20130074808A (ko) *	2011-12-16	2013-07-05	한올바이오파마주식회사	스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물
RU2015106909A (ru)	2012-08-02	2016-09-27	Мерк Шарп И Доум Корп.	Антидиабетические трициклические соединения
KR20150118158A (ko)	2013-02-22	2015-10-21	머크 샤프 앤드 돔 코포레이션	항당뇨병 비시클릭 화합물
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
ES2698363T3 (es) *	2013-03-14	2019-02-04	Actimed Therapeutics Ltd	Composiciones de oxprenolol para tratar el cáncer
AU2014235215A1 (en)	2013-03-15	2015-10-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt)	2013-06-05	2017-08-29	Synergy Pharmaceuticals Inc	Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
EP2832357A1 (en)	2013-07-29	2015-02-04	Charité - Universitätsmedizin Berlin	Selective AT2 receptor agonists for use in treatment of cachexia
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
KR102431436B1 (ko)	2014-08-29	2022-08-10	테스 파마 에스.알.엘.	α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
EP3419610A4 (en)	2016-02-26	2019-10-16	Actimed Therapeutics Ltd	S-ENANTIOMER ENHANCED COMPOSITIONS OF BETA LOAD FOR THE TREATMENT OF MUSCLE WEAKNESSES
WO2018069532A1 (en)	2016-10-14	2018-04-19	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
EP3558298B1 (en)	2016-12-20	2026-03-11	Merck Sharp & Dohme LLC	Antidiabetic spirochroman compounds
US10799138B2 (en)	2018-04-05	2020-10-13	University Of Maryland, Baltimore	Method of administering sotalol IV/switch
US11610660B1 (en)	2021-08-20	2023-03-21	AltaThera Pharmaceuticals LLC	Antiarrhythmic drug dosing methods, medical devices, and systems
US10512620B1 (en)	2018-08-14	2019-12-24	AltaThera Pharmaceuticals, LLC	Method of initiating and escalating sotalol hydrochloride dosing
US11696902B2 (en)	2018-08-14	2023-07-11	AltaThera Pharmaceuticals, LLC	Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en)	2021-08-20	2025-08-26	AltaThera Pharmaceuticals LLC	Anti-arrhythmic compositions and methods
US11344518B2 (en)	2018-08-14	2022-05-31	AltaThera Pharmaceuticals LLC	Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
AR117122A1 (es)	2018-11-20	2021-07-14	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US10772869B1 (en)	2019-07-24	2020-09-15	ECI Pharmaceuticals, LLC	Pharmaceutical compositions including carvedilol and methods of using the same
GB2593902B (en)	2020-04-07	2022-04-13	Actimed Therapeutics Ltd	Salt of a pharmaceutical compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5541188A (en) *	1987-09-15	1996-07-30	The Rowett Research Institute	Therapeutic applications of beta-adrenergic agonists
CA1337432C (en)	1988-03-23	1995-10-24	Raymond M. Xhonneux	Method of lowering the blood pressure
US6545040B1 (en) *	1988-03-23	2003-04-08	Janssen Pharmaceutica N.V.	Method of lowering the blood pressure
EP0519925A1 (en) *	1989-11-21	1992-12-30	Sepracor, Inc.	Use of optically pure s(-) atenolol for the treatment of cardiovascular disorders
EP0714663A3 (en)	1994-11-28	1997-01-15	Lilly Co Eli	Potentiation of drug responses by serotonin 1A receptor antagonists
EP1136078A3 (en) *	1995-02-10	2002-07-24	G.D. Searle & Co.	Combination of angiotensin converting enzyme inhibitor and side- effect-reduced amount of aldosterone antagonist
JPH0971586A (ja)	1995-09-07	1997-03-18	Yamanouchi Pharmaceut Co Ltd	新規な二環性縮合イミダゾール誘導体
AUPO274596A0 (en)	1996-10-04	1996-10-31	Armstrong, Stuart Maxwell	Method for the treatment of neurological or neuropsychiatric disorders
GB9714675D0 (en)	1997-07-11	1997-09-17	Smithkline Beecham Plc	Novel composition
US7417038B1 (en) *	1998-10-15	2008-08-26	Imperial Innovations Limited	Methods of treating cachexia
CZ20022410A3 (cs) *	2000-01-31	2003-08-13	Pfizer Products Inc.	Benzoanelované heterocyklylové deriváty nikotinamidu užitečné jako selektivní inhibitory isozymů PDE4
ATE409475T1 (de) *	2001-02-20	2008-10-15	Dinan Timothy Gerard	Behandlung von fibromyalgie mit pindolol
JP2008513430A (ja)	2004-09-17	2008-05-01	ニューロキュアリミテッド	月経前症候群および月経前不快気分障害の処置のためのピンドロール
JP2008514612A (ja)	2004-09-23	2008-05-08	ミシャロウ、アレクサンダー	対抗適応を誘発することにより神経伝達物質系を調節する方法
WO2006102476A2 (en)	2005-03-21	2006-09-28	Vicus Therapeutics Spe 1, Llc	Compositions and methods for ameliorating cachexia
JP2009526087A (ja)	2005-12-22	2009-07-16	アナボレックス，インコーポレイテッド	悪液質の予防および処置のための組成物および方法
JP2009528289A (ja)	2006-02-27	2009-08-06	ミシャロウ、アレクサンダー	対抗適応を誘発することにより神経伝達物質系を調節する方法
AU2007316613B2 (en)	2006-11-09	2013-11-28	Boehringer Ingelheim International Gmbh	Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
AU2008240379B2 (en)	2007-04-24	2012-10-04	Acacia Pharma Limited	Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss
WO2009111648A1 (en)	2008-03-05	2009-09-11	Vicus Therapeutics, Llc	Compositions and methods for mucositis and oncology therapies

1999
- 1999-10-15 US US09/807,558 patent/US7417038B1/en not_active Expired - Fee Related
- 1999-10-15 WO PCT/GB1999/003302 patent/WO2000021509A2/en not_active Ceased
- 1999-10-15 JP JP2000575485A patent/JP2002527378A/ja active Pending
- 1999-10-15 DE DE69942009T patent/DE69942009D1/de not_active Expired - Lifetime
- 1999-10-15 AT AT99947762T patent/ATE457169T1/de active
- 1999-10-15 PT PT99947762T patent/PT1121111E/pt unknown
- 1999-10-15 EP EP99947762A patent/EP1121111B1/en not_active Expired - Lifetime
- 1999-10-15 DK DK99947762.3T patent/DK1121111T3/da active
2008
- 2008-08-15 US US12/192,780 patent/US7829596B2/en not_active Expired - Fee Related
2010
- 2010-05-10 CY CY20101100408T patent/CY1110282T1/el unknown

Also Published As

Publication number	Publication date
WO2000021509A3 (en)	2000-11-09
EP1121111A2 (en)	2001-08-08
PT1121111E (pt)	2010-05-17
US20090023639A1 (en)	2009-01-22
US7417038B1 (en)	2008-08-26
CY1110282T1 (el)	2015-01-14
JP2002527378A (ja)	2002-08-27
ATE457169T1 (de)	2010-02-15
DE69942009D1 (de)	2010-03-25
WO2000021509A2 (en)	2000-04-20
US7829596B2 (en)	2010-11-09
EP1121111B1 (en)	2010-02-10

Publication	Publication Date	Title
DK1121111T3 (da)	2010-05-31	Forbindelser til behandling af vægttab
ATE334985T1 (de)	2006-08-15	Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
IL149890A0 (en)	2002-11-10	Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated
EP1059100A3 (en)	2003-12-03	Combinations of CRF antagonists and renin-angiotensin system inhibitors
NO990912D0 (no)	1999-02-25	Terapeutiske kombinasjoner av PAR-antagonister og RXR-antagonister og deres anvendelse
WO2004017941A3 (en)	2004-04-22	Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
WO2001001972A3 (en)	2001-12-06	SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2005047244A3 (en)	2006-12-21	Inhibition of fgfr3 and treatment of multiple myeloma
MY114347A (en)	2002-10-31	Synergistic therapeutic compositions and methods.
WO2003092606A3 (en)	2004-01-08	Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2000048446A3 (en)	2001-02-08	Use of antagonists of pg-e for the treatment of neuropathic pain
EP1090635A3 (en)	2002-02-27	Use of ferulic acid for treating hypertension
IS4847A (is)	1998-09-15	Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni
MY126321A (en)	2006-09-29	Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
WO2001055176A3 (en)	2002-07-25	Methods for inhibiting smooth muscle cell proliferation
WO2006053014A3 (en)	2006-08-24	Selective inhibition of rock1 in cardiac therapy
DK1503764T3 (da)	2010-05-10	5-HT4-receptor-antagonister til behandling af hjertesvigt
MXPA02007454A (es)	2004-08-23	Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor.
ECSP003564A (es)	2001-04-23	ANTAGONISTAS SELECTIVOS DEL RECEPTOR DE iG1uR5 PARA EL TRATAMIENTO DE LA MIGRAÑA
EP1095655A3 (en)	2003-03-26	NK-1 receptor antagonists and eletriptan for the treatment of migraine